【摘要】 目的探讨射频消融(radiofrequency Ablation,RFA)联合索拉非尼和干扰素治疗复发性肝癌的安全性和疗效。方法回顾性分析2006年1月~2013年12月期间69例行RFA联合索拉非尼治疗复发性肝癌患者的临床病例资料,根据是否使用干扰素分为干扰素组(n=34例)和对照组(n=35例)。比较两组患者治疗期间并发症的发生率,1、3和5年无瘤生存率和总体生存率等。结果两组患者的临床病理资料比较无统计学差异。与对照组相比,干扰素组治疗期间的并发症的发生率无明显增加(17.6%比17.1%,P=0.96)。干扰素组1、3和5年无瘤生存率分别为56.5%、21.2%和7.6%,而对照组分别为41.7%、22.7%和5.3%,组间比较差异无统计学意义(P=0.99)。干扰素组1、3和5年总体生存率分别为87.9%、45.1%和12.0%,而对照组分别为84.3%、27.4%和6.8%,组间比较差异具有统计学意义(P=0.04)。结论对于复发性肝癌患者,RFA联合索拉非尼和干扰素治疗复发性肝癌是安全、有效的,虽然不能延长患者无瘤生存率,但可提高患者的生活质量,延长患者的总体生存率。更多还原

【Abstract】 Objective To investigate the clinical effects and safety of radiofrequency ablation( RFA),sorafenib and interferon-α( IFN-α) for patients with recurrent hepatocellular carcinoma( HCC) after curative resection. Methods The clinical data of 69 cases diagnosed with recurrent HBV-related HCC and underwent curative resection between January 2006 and December 2013 were analyzed retrospectively. The 69 patients were divided into IFN group( n = 34) and controlled group( n = 35) for treating recurrent HCC according to carry out IFN-α therapy or not. The complication rates,1-,3-and 5-year disease-free survival and overall survival rates were evaluated and compared between two groups. Results The clinicopathological parameters and adverse effects were similar between the two groups( P > 0. 05). Compared with the controlled group,the complication rate of IFN group had not statistic difference( 17. 6% vs. 17. 1%,P = 0. 96). The 1-,3-and 5-year disease-free survival rates were 56. 5%,21. 2% and 7. 6% in the IFN group respectively,and were 41. 7%,22. 7% and 5. 3% in the controlled group respectively,there was no statistic difference between two groups( P = 0. 99). Whereas the 1-,3- and 5-year overall survival rates were 87. 9%,45. 1%and 12. 0% respectively in the IFN group,those were better than 84. 3%,27. 4% and 6. 8% respectively in the controlled group( P = 0. 04). Conclusion The treatment of RFA therapy,sorafenib and IFN-α is safe and effective for recurrent HCC after curative resection,and it can improve the overall survival in patients with HBV-related HCC.更多还原